Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (20 quarters reported)
$214M in Q4 2021 → $3.54B now. Hover for any quarter.
As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| AS Abivax Sa American Depositary Shares | 10.2% | Trimmed 39% | 3,663,038 | $363M |
| Cg Oncology Inc | 7.4% | Unchanged | 3,670,206 | $260M |
| Amylyx Pharmaceuticals Inc | 5.1% | Unchanged | 6,243,812 | $182M |
| Spyre Therapeutics Inc | 4.8% | Unchanged | 1,900,582 | $169M |
| Tango Therapeutics Inc | 4.8% | Trimmed 25% | 6,773,043 | $169M |
| ZL Zai Lab Ltd-adr | 4.6% | Added 1.5% | 6,229,081 | $164M |
| Immunovant Inc | 4.3% | Unchanged | 4,457,988 | $151M |
| Dianthus Therapeutics Inc | 4.2% | Unchanged | 1,676,624 | $148M |
| Korsana Biosciences Inc | 4.1% | New | 4,549,587 | $146M |
| Kodiak Sciences Inc | 3.9% | Unchanged | 1,445,538 | $137M |
| Vor Biopharma Inc | 3.1% | Unchanged | 5,673,078 | $108M |
| First Tracks Biotherapeutics | 2.9% | Unchanged | 2,895,304 | $103M |
| Mirum Pharmaceuticals Inc | 2.7% | Added 5.4% | 1,118,967 | $95.6M |
| Biocryst Pharmaceuticals Inc | 2.6% | Unchanged | 11,020,968 | $91.8M |
| Disc Medicine Inc | 2.5% | Unchanged | 1,341,862 | $87.8M |
| Adarx Pharmaceuticals Inc | 2.3% | New | 4,116,452 | $82.1M |
| Cogent Biosciences Inc | 2.3% | Trimmed 49% | 2,500,003 | $80.1M |
| Tyra Biosciences Inc | 2.1% | Added 7.0% | 3,475,980 | $76M |
| Dyne Therapeutics Inc | 2.1% | Unchanged | 4,615,144 | $74.3M |
| Relay Therapeutics Inc | 1.9% | Trimmed 11% | 3,783,529 | $68.3M |
| Aura Biosciences Inc | 1.8% | Added 6.6% | 10,165,357 | $63.8M |
| Savara Inc | 1.8% | Unchanged | 12,362,205 | $63.8M |
| Xencor Inc | 1.4% | Trimmed 16% | 2,055,938 | $51.3M |
| Avalo Therapeutics Inc | 1.3% | Unchanged | 3,017,120 | $46.3M |
| Monte Rosa Therapeutics Inc | 1.3% | Trimmed 18% | 3,781,532 | $45.1M |
| Mbx Biosciences Inc | 1.1% | Unchanged | 650,000 | $38.1M |
| Entera Bio Ltd | 1.0% | New | 12,254,901 | $35.7M |
| Janux Therapeutics Inc | 0.9% | Unchanged | 1,789,617 | $30.9M |
| Tarsus Pharmaceuticals Inc | 0.9% | New | 388,164 | $30.5M |
| Century Therapeutics Inc | 0.9% | Unchanged | 17,754,430 | $30.4M |
| Obsidian Therapeutics Inc | 0.9% | New | 2,196,138 | $30.2M |
| PB Pharvaris Bv | 0.8% | Trimmed 6.0% | 947,544 | $30.1M |
| Lb Pharmaceuticals Inc | 0.8% | Trimmed 47% | 765,050 | $29.4M |
| Editas Medicine Inc | 0.8% | Unchanged | 11,111,111 | $28.6M |
| Tectonic Therapeutic Inc | 0.8% | Unchanged | 1,204,891 | $28.1M |
| Inflarx N V | 0.7% | Unchanged | 14,500,000 | $26.1M |
| Perspective Therapeutics Inc | 0.6% | Unchanged | 7,915,567 | $21.8M |
| Agomab Therapeutics Nv | 0.6% | Trimmed 11% | 1,820,831 | $20.2M |
| Silence Therapeutics PLC | 0.6% | Trimmed 40% | 1,819,035 | $19.9M |
| Alector Inc | 0.5% | Unchanged | 10,000,000 | $18.5M |
| Biohaven Ltd | 0.5% | Trimmed 29% | 1,262,423 | $16.9M |
| Monopar Therapeutics Inc | 0.5% | Trimmed 0.5% | 202,242 | $16.1M |
| Adc Therapeutics Sa | 0.4% | Unchanged | 11,390,175 | $13.9M |
| Entrada Therapeutics Inc | 0.2% | Unchanged | 1,060,230 | $6.73M |
| Cullinan Therapeutics Inc | 0.2% | Unchanged | 406,786 | $6.24M |
| Agenus Inc | 0.2% | New | 603,892 | $6M |
| Ocular Therapeutix Inc | 0.2% | Trimmed 56% | 720,323 | $5.52M |
| Arvinas Inc | 0.2% | Unchanged | 707,098 | $5.47M |
| Korro Bio Inc | 0.1% | Unchanged | 416,301 | $4.13M |
| RA Research Alliance Corp Iv-a | 0.1% | New | 300,000 | $3.6M |
| Alx Oncology Holdings Inc | 0.1% | Trimmed 56% | 2,465,436 | $3.43M |
| Aktis Oncology Inc | 0.1% | Trimmed 81% | 133,457 | $2.6M |
| Jatt Ii Acquisition Corp | 0.1% | Unchanged | 200,000 | $2.25M |
| Leonabio Inc | 0.0% | Unchanged | 464,398 | $1.66M |
| Jatt Iii Acquisition Corp | 0.0% | New | 100,000 | $1.1M |
| Context Therapeutics Inc | 0.0% | Unchanged | 2,682,696 | $806K |
| Eikon Therapeutics Inc | 0.0% | Unchanged | 37,902 | $305K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2026 · filed November 16, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AS Abivax Sa American Depositary Shares | Trimmed | −2,344,796 | −$232M | 10.2% |
| Korsana Biosciences Inc | New | +4,549,587 | +$146M | 4.1% |
| Adarx Pharmaceuticals Inc | New | +4,116,452 | +$82.1M | 2.3% |
| Cogent Biosciences Inc | Trimmed | −2,354,433 | −$75.4M | 2.3% |
| Revolution Medicines Inc | Exited | −340,899 | −$63.8M | — |
| Tango Therapeutics Inc | Trimmed | −2,308,158 | −$57.6M | 4.8% |
| Surrozen Inc | Exited | −1,473,101 | −$38.2M | — |
| Entera Bio Ltd | New | +12,254,901 | +$35.7M | 1.0% |
| Tarsus Pharmaceuticals Inc | New | +388,164 | +$30.5M | 0.9% |
| Altimmune Inc | Exited | −10,000,000 | −$30.4M | — |
Showing the 10 largest of 32 changes.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Centessa Pharmaceuticals PLC | Exited | −4,286,480 | −$170M | — |
| ZL Zai Lab Ltd-adr | New | +6,137,627 | +$117M | 2.8% |
| Aura Biosciences Inc | New | +9,533,333 | +$67.7M | 1.6% |
| AS Abivax Sa American Depositary Shares | Trimmed | −473,251 | −$63.1M | 19.2% |
| First Tracks Biotherapeutics | New | +2,895,304 | +$58.3M | 1.4% |
| Tango Therapeutics Inc | Trimmed | −1,449,870 | −$45.3M | 6.8% |
| Revolution Medicines Inc | Trimmed | −235,574 | −$44.1M | 1.5% |
| Biohaven Ltd | Trimmed | −2,851,365 | −$42.4M | 0.6% |
| Avalo Therapeutics Inc | Added | +2,278,737 | +$42.1M | 1.3% |
| Fulcrum Therapeutics Inc | Exited | −5,250,000 | −$40.3M | — |
Showing the 10 largest of 30 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc | New | +11,020,968 | +$105M | 3.0% |
| Vor Biopharma Inc | New | +5,673,078 | +$96.5M | 2.8% |
| Mirum Pharmaceuticals Inc | Added | +1,000,000 | +$92.4M | 2.8% |
| Rapt Therapeutics Inc | Exited | −2,582,408 | −$87.5M | — |
| Disc Medicine Inc | New | +1,341,862 | +$85.8M | 2.5% |
| AS Abivax Sa American Depositary Shares | Trimmed | −630,511 | −$70.2M | 20.6% |
| Immunovant Inc | Added | +2,797,055 | +$69.5M | 3.2% |
| Eyepoint Pharmaceuticals Inc | Exited | −3,572,335 | −$65.3M | — |
| LT Liquidia Technologies Inc | Trimmed | −1,307,036 | −$49.3M | 0.4% |
| Tango Therapeutics Inc | Trimmed | −2,231,023 | −$46.7M | 6.3% |
Showing the 10 largest of 34 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Monte Rosa Therapeutics Inc | New | +4,622,151 | +$72.5M | 2.4% |
| Tourmaline Bio Inc | Exited | −1,311,783 | −$62.7M | — |
| Biohaven Ltd | New | +4,631,317 | +$52.3M | 1.7% |
| Immunovant Inc | New | +1,660,933 | +$42.2M | 1.4% |
| Tango Therapeutics Inc | Added | +4,225,898 | +$37.4M | 3.7% |
| Upstream Bio Inc | Trimmed | −1,373,217 | −$37.3M | 0.7% |
| Adc Therapeutics Sa | Added | +10,000,000 | +$35.3M | 1.3% |
| Cogent Biosciences Inc | Trimmed | −930,000 | −$33M | 6.9% |
| Rapt Therapeutics Inc | Added | +946,133 | +$32M | 2.9% |
| Disc Medicine Inc | Exited | −465,257 | −$30.7M | — |
Showing the 10 largest of 29 changes.
quarter ended September 30, 2025 · filed November 17, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AS Abivax Sa American Depositary Shares | Added | +1,055,000 | +$89.6M | 29.7% |
| Cidara Therapeutics Inc | Exited | −1,005,901 | −$49M | — |
| LT Liquidia Technologies Inc | New | +1,710,084 | +$38.9M | 1.9% |
| Agios Pharmaceuticals Inc | Added | +733,038 | +$29.4M | 2.8% |
| Lb Pharmaceuticals Inc | New | +1,745,016 | +$27.6M | 1.4% |
| Revolution Medicines Inc | New | +436,473 | +$20.4M | 1.0% |
| Korro Bio Inc | New | +416,301 | +$19.9M | 1.0% |
| Tango Therapeutics Inc | Trimmed | −2,199,804 | −$18.5M | 3.5% |
| Spyre Therapeutics Inc | New | +1,100,582 | +$18.4M | 0.9% |
| Soleno Therapeutics Inc | Exited | −186,250 | −$15.6M | — |
Showing the 10 largest of 32 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Mineralys Therapeutics Inc | Exited | −2,470,265 | −$39.2M | — |
| Agios Pharmaceuticals, Inc. | New | +697,003 | +$23.2M | 2.6% |
| Rapt Therapeutics, Inc. | Exited | −13,090,200 | −$16M | — |
| Rapt Therapeutics, Inc. | New | +1,636,275 | +$13.1M | 1.5% |
| Compass Pathways Ltd | Exited | −3,858,000 | −$11M | — |
| Dyne Therapeutics Inc | Added | +1,116,510 | +$10.6M | 4.1% |
| Enliven Therapeutics, Inc. | New | +498,000 | +$9.99M | 1.1% |
| Soleno Therapeutics Inc | Trimmed | −88,750 | −$7.44M | 1.8% |
| Nektar Therapeutics | New | +266,666 | +$6.89M | 0.8% |
| Aerovate Therapeutics Inc | Exited | −2,240,809 | −$5.62M | — |
Showing the 10 largest of 14 changes.
quarter ended March 31, 2025 · filed May 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Soleno Therapeutics Inc | Trimmed | −275,000 | −$19.6M | 2.7% |
| Tyra Biosciences Inc | Added | +909,000 | +$8.45M | 3.7% |
| Amylyx Pharmaceuticals Inc | Added | +1,300,000 | +$4.6M | 2.9% |
| Disc Medicine Inc | Trimmed | −21,700 | −$1.08M | 3.2% |
| Rapt Therapeutics, Inc. | Trimmed | −45,060 | −$55K | 2.2% |
| Keros Therapeutics Inc | Trimmed | −550,000 | — | — |
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Edgewise Therapeutics, Inc. | Exited | −2,112,984 | −$56.4M | — |
| Upstream Bio Inc | New | +2,801,763 | +$44.9M | 4.4% |
| Tango Therapeutics Inc | New | +10,736,000 | +$33.2M | 3.2% |
| Dianthus Therapeutics Inc | New | +1,501,624 | +$32.7M | 3.2% |
| Cidara Therapeutics, Inc. | New | +1,005,901 | +$26.1M | 2.5% |
| Rapt Therapeutics, Inc. | New | +13,135,260 | +$19.8M | 1.9% |
| Eyepoint Pharmaceuticals Inc | Added | +2,650,000 | +$19.7M | 2.6% |
| Tarsus Pharmaceuticals, Inc. | Exited | −231,820 | −$7.62M | — |
| Keros Therapeutics Inc | Trimmed | −329,344 | −$5.21M | 0.9% |
| An2 Therapeutics, Inc. | Exited | −1,555,118 | −$1.66M | — |
Showing the 10 largest of 14 changes.
Loading...